- Smoking history and exhaled carbon monoxide levels are both associated with a lower risk of developing Parkinson’s disease.
- In a new study, researchers set out to better understand this link. They found that participants who had not smoked but had high exhaled carbon monoxide levels also had lower risk of Parkinson’s disease.
- Having higher exhaled carbon monoxide levels was not linked to a lower risk of other neurodegenerative diseases.
A new study may have shed some light on the peculiar association between smoking and a lower risk of developing Parkinson’s disease.
The study, published in
Parkinson’s disease is a brain condition that is growing increasingly common. The World Health Organization (WHO) estimates that its prevalence
The disease causes damage to nerve cells in an area of the brain called the substantia nigra, resulting in symptoms such as tremors and coordination problems. Some people with Parkinson’s go on to develop dementia over time.
Experts are unsure what causes Parkinson’s at present, but believe that genetic changes or environmental exposures may play a role.
While studies in rodent models led researchers to suggest that nicotine might have some kind of protective effect, a recent randomized clinical trial found that nicotine therapy provided no benefit to people with Parkinson’s. In fact, the trial suggested the nicotine may have even made their symptoms worse.
As a result, an international team of researchers set out to see how carbon monoxide exposure might relate to the risk of Parkinson’s disease.
The researchers examined data from 512,701 participants in the China Kadoorie Biobank, a cohort coming from 10 different urban and rural areas within China. The participants had a mean average of 52 years at the beginning of the study.
Participants provided information about their smoking history along with other aspects of their lifestyle and medical history via questionnaires. Clinicians also measured the amount of carbon monoxide they exhaled.
The researchers examined the health outcomes of the participants over a follow-up period of 12 years. During this time, they noted a total of 1,131 people developing Parkinson’s disease and 2,949 developing other forms of neurodegenerative disease.
They then looked to see if there were any patterns between these health outcomes, smoking histories, and measurements of exhaled carbon monoxide taken at the beginning of the study period.
Exhaled carbon monoxide levels were much higher in regular smokers than those who never smoked, occasionally smoked, or previously smoked regularly.
The researchers found that regular smoking was associated with a lower risk of Parkinson’s disease, aligning with what previous population studies had found.
In those who had never smoked, however, higher exhaled carbon monoxide levels were also associated with a lower risk of Parkinson’s disease. This seemed to be dose-dependent, with the higher levels conveying a lower risk.
Higher carbon monoxide levels were also not associated with the risk of smoking-related diseases such as lung cancer in people who had not smoked, nor were they associated with the risk of other neurodegenerative diseases.
“This study demonstrates the power of longitudinal patient data,” said study author associate professor Andrea Bugarcic, PhD, from the National Center for Naturopathic Medicine at Southern Cross University, Australia, in a press release.
“Combining what patients say about their lives, such as smoking and environment, with measurements we can make as scientists, such as exhaled carbon monoxide, the study links higher exhaled carbon monoxide to a lower risk of Parkinson’s disease only, not other causes of dementia,” added Bugarcic.
The researchers believe this study is another step toward refuting the idea that tobacco smoking specifically could help protect against Parkinson’s disease.
“While increased exhaled carbon monoxide is linked to smoking, the current study also points out that risk levels for nonsmoking and smoking patients are the same,” explained Bugarcic.
“Collectively, the study not only points out a possible mechanism for the previously observed protective effects of smoking on Parkinson’s disease risk, but it also reminds us that carbon monoxide release is a larger environmental consideration,” she pointed out.
In a Science Media Centre debrief, Senior Research Fellow in Parkinson’s epidemiology at the University of Otago in New Zealand, Toni Pitcher, PhD, who was not involved with the study, said:
“This is the first large-scale demonstration that Parkinson’s is also less common in individuals with higher levels of exhaled carbon monoxide in the absence of a smoking history. Carbon monoxide has anti-inflammatory effects, and in the brain helps to counteract cell stress. There is the potential that individuals with higher internal levels of carbon monoxide are more able to fight off inflammatory processes and better maintain brain health.”
While these findings are of great interest, there are some key aspects to the study that need consideration.
A key limitation was that the participants only provided carbon monoxide measurements and smoking histories at the very beginning of the study. Their circumstances may have changed over the 12-year follow-up period.
The researchers also had no data on Parkinson’s disease from primary care settings or other institutions, relying solely on death and disease registries and the health insurance system. This means they did not have access to the full picture of what happened with their participants.
Finally, with a mean average age of 52, the cohort the researchers followed was relatively young for a Parkinson’s disease study, as most people develop the disease
These limitations mean that it is harder to generalize the results to a wider population, and suggest that more research is needed to confirm these findings.
Salvador Ventura, PhD, a professor of biochemistry and molecular biology at the Autonomous University of Barcelona in Spain, who was not involved in the study, also noted in a Science Media Centre debrief that:
“The fact that something is associated with a lower incidence of the disease says nothing about whether administering it would slow its progression in someone who has already been diagnosed. These are two distinct questions, and this research addresses only the first.“
“Before discussing clinical applications, the observation would need to be replicated in other populations and safety and efficacy demonstrated in controlled trials,” added Ventura.
It is important to emphasize that these findings do not suggest that taking up smoking is a good idea in any way.
“These findings do not justify taking up smoking or delaying giving up smoking; the study itself finds, as might be expected, higher rates of lung cancer, cardiovascular disease, and mortality amongst smokers,” said Ventura. “Nor do they justify deliberately exposing oneself to a gas that causes severe poisoning.”
The study authors note that trials are currently underway to test a liquid drug form of low-dose carbon monoxide in people with Parkinson’s disease.
Aside from this, they hope that this study will encourage others to dig deeper into the origins of Parkinson’s disease.
“Despite the controversial outcomes and limitations of this study, my perspective is that researchers across the methodological spectrum should take on the challenge set out by this study — understand why and how exhaling more carbon monoxide links specifically to lower Parkinson’s disease risk,” said Bugarcic.
“This is where studies like this matter — they give a voice to patients that then mobilizes all that science has to offer, from understanding why to ensuring a grounded approach to therapeutic development,” she concluded.
